{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:10:50Z","timestamp":1785557450244,"version":"3.56.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008530","name":"FEDER","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"FCT"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ejpb.2018.02.001","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T07:26:34Z","timestamp":1517556394000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Composite films for vaginal delivery of tenofovir disoproxil fumarate and emtricitabine"],"prefix":"10.1016","volume":"138","author":[{"given":"Mafalda Pereira","family":"Cautela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hen","family":"Moshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Sosnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-2759","authenticated-orcid":false,"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"das Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2018.02.001_b0005","unstructured":"World Health Organization, Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV, Geneva, Switzerland, 2015."},{"key":"10.1016\/j.ejpb.2018.02.001_b0010","unstructured":"PrEPWatch, Country Updates. Available from URL: <http:\/\/www.prepwatch.org\/advocacy\/country-updates\/> (accessed Dec 9, 2017)."},{"key":"10.1016\/j.ejpb.2018.02.001_b0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2018.02.001_b0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2018.02.001_b0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2018.02.001_b0030","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"VOICE Study Team, Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2018.02.001_b0035","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2018.02.001_b0040","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1097\/QAD.0b013e3283629037","article-title":"Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial","volume":"27","author":"Murnane","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.ejpb.2018.02.001_b0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2055-6640(20)30458-1","article-title":"HIV pre-exposure prophylaxis for women","volume":"2","author":"Sheth","year":"2016","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.ejpb.2018.02.001_b0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/infdis\/jiw077","article-title":"A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine","volume":"214","author":"Cottrell","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejpb.2018.02.001_b0055","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","article-title":"HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention","volume":"66","author":"Donnell","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejpb.2018.02.001_b0060","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2018.02.001_b0065","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-med-050911-163701","article-title":"Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis","volume":"64","author":"Baeten","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejpb.2018.02.001_b0070","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/jcph.292","article-title":"Topical microbicides and HIV prevention in the female genital tract","volume":"54","author":"Cottrell","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2018.02.001_b0075","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2018.02.001_b0080","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"MTN-Aspire Study Team, Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"Baeten","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2018.02.001_b0085","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"Nel","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2018.02.001_b0090","doi-asserted-by":"crossref","first-page":"e0157061","DOI":"10.1371\/journal.pone.0157061","article-title":"Topical delivery of tenofovir disoproxil fumarate and emtricitabine from pod-intravaginal rings protects macaques from multiple SHIV exposures","volume":"11","author":"Srinivasan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2018.02.001_b0095","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1128\/AAC.02871-14","article-title":"Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model","volume":"58","author":"Moss","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2018.02.001_b0100","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/pharmaceutics6040616","article-title":"Evaluation of rapidly disintegrating vaginal tablets of tenofovir, emtricitabine and their combination for HIV-1 prevention","volume":"6","author":"Clark","year":"2014","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2018.02.001_b0105","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1089\/jwh.2010.2476","article-title":"Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women","volume":"20","author":"Nel","year":"2011","journal-title":"J. Womens Health (Larchmt.)"},{"key":"10.1016\/j.ejpb.2018.02.001_b0110","series-title":"Drug Delivery and Development of Anti-HIV Microbicides","first-page":"291","article-title":"Vaginal microbicide films","author":"Rohan","year":"2014"},{"key":"10.1016\/j.ejpb.2018.02.001_b0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.addr.2015.02.001","article-title":"Mucoadhesive and thermogelling systems for vaginal drug delivery","volume":"92","author":"Caramella","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2018.02.001_b0120","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/17425247.2017.1270938","article-title":"Antiretroviral drug-loaded nanoparticles-in-films: a new option for developing vaginal microbicides?","volume":"14","author":"das Neves","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2018.02.001_b0125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cis.2015.05.003","article-title":"Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers","volume":"223","author":"Sosnik","year":"2015","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2018.02.001_b0130","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1128\/AAC.00450-16","article-title":"Topical tenofovir disoproxil fumarate nanoparticles prevent HIV-1 vaginal transmission in a humanized mouse model","volume":"60","author":"Destache","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2018.02.001_b0135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jconrel.2016.09.020","article-title":"Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs","volume":"243","author":"Cunha-Reis","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2018.02.001_b0140","doi-asserted-by":"crossref","first-page":"16145","DOI":"10.1073\/pnas.1311355110","article-title":"Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges","volume":"110","author":"Smith","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejpb.2018.02.001_b0145","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.actbio.2016.08.018","article-title":"Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system","volume":"44","author":"Machado","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2018.02.001_b0150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0010-7824(99)00010-4","article-title":"A vaginal fluid simulant","volume":"59","author":"Owen","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.ejpb.2018.02.001_b0155","first-page":"64","article-title":"Mathematical comparison of dissolution profiles","volume":"20","author":"Moore","year":"1996","journal-title":"Pharm. Tech."},{"key":"10.1016\/j.ejpb.2018.02.001_b0160","unstructured":"International Organization for Standardization, ISO 10993-5:2009 Biological Evaluation of Medical Devices \u2013 Part 5: Tests for In Vitro Cytotoxicity, Geneva, Switzerland."},{"key":"10.1016\/j.ejpb.2018.02.001_b0165","doi-asserted-by":"crossref","first-page":"e0184303","DOI":"10.1371\/journal.pone.0184303","article-title":"Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice","volume":"12","author":"Gallay","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2018.02.001_b0170","article-title":"Impact of the dapivirine vaginal ring on sexual experiences and intimate partnerships of women in an HIV prevention clinical trial: managing ring detection and hot sex","author":"Laborde","year":"2017","journal-title":"AIDS Behav."},{"key":"10.1016\/j.ejpb.2018.02.001_b0175","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijpharm.2016.01.020","article-title":"Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: state-of-the-art and challenges","volume":"499","author":"Ramazani","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.02.001_b0180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/17425247.2013.736962","article-title":"Eudragit: a technology evaluation","volume":"10","author":"Thakral","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2018.02.001_b0185","first-page":"209","article-title":"Suspension stability; why particle size, zeta potential and rheology are important","volume":"20","author":"Larsson","year":"2012","journal-title":"Ann. Trans. Nord. Rheol. Soc."},{"key":"10.1016\/j.ejpb.2018.02.001_b0190","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0939-6411(03)00193-0","article-title":"Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles","volume":"57","author":"Bootz","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.02.001_b0195","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejps.2015.02.009","article-title":"Engineering of a hybrid polymer-lipid nanocarrier for the nasal delivery of tenofovir disoproxil fumarate: physicochemical, molecular, microstructural, and stability evaluation","volume":"71","author":"Pokharkar","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.02.001_b0200","doi-asserted-by":"crossref","first-page":"e01475-16","DOI":"10.1128\/AAC.01475-16","article-title":"An enhanced emtricitabine-loaded long-acting nanoformulation for prevention or treatment of HIV infection","volume":"61","author":"Mandal","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2018.02.001_b0205","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.colsurfb.2011.09.038","article-title":"Nano and microparticle engineering of water insoluble drugs using a novel spray-drying process","volume":"90","author":"Schafroth","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejpb.2018.02.001_b0210","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.colsurfb.2014.09.055","article-title":"Spray-dried didanosine-loaded polymeric particles for enhanced oral bioavailability","volume":"123","author":"Seremeta","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejpb.2018.02.001_b0215","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s11095-014-1474-4","article-title":"Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention","volume":"32","author":"Akil","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2018.02.001_b0220","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/pharmaceutics6030530","article-title":"Characterization of commercially available vaginal lubricants: a safety perspective","volume":"6","author":"Cunha","year":"2014","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2018.02.001_b0225","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijpharm.2013.11.033","article-title":"Mechanical strength test for orodispersible and buccal films","volume":"461","author":"Preis","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.02.001_b0230","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10508-016-0816-1","article-title":"Preferred physical characteristics of vaginal film microbicides for HIV prevention in Pittsburgh women","volume":"46","author":"Fan","year":"2016","journal-title":"Arch. Sex. Behav."},{"key":"10.1016\/j.ejpb.2018.02.001_b0235","doi-asserted-by":"crossref","first-page":"e48328","DOI":"10.1371\/journal.pone.0048328","article-title":"Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity","volume":"7","author":"Dezzutti","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2018.02.001_b0240","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.ijir.3900977","article-title":"A journey through two lumens!","volume":"15","author":"Levin","year":"2003","journal-title":"Int. J. Impot. Res."},{"key":"10.1016\/j.ejpb.2018.02.001_b0245","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2014.12.005","article-title":"Preclinical assessments of vaginal microbicide candidate safety and efficacy","volume":"92","author":"Fern\u00e1ndez-Romero","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2018.02.001_b0250","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.actbio.2015.02.007","article-title":"Precise engineering of dapivirine-loaded nanoparticles for the development of anti-HIV vaginal microbicides","volume":"18","author":"das Neves","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2018.02.001_b0255","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1128\/AAC.49.4.1509-1520.2005","article-title":"Comparative safety evaluation of the candidate vaginal microbicide C31G","volume":"49","author":"Catalone","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2018.02.001_b0260","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1128\/AAC.00456-10","article-title":"In vitro evaluation of viability, integrity and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides","volume":"54","author":"Gali","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2018.02.001_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.qai.0000159671.25950.74","article-title":"In vitro and in vivo: the story of nonoxynol 9","volume":"39","author":"Hillier","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641117314467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641117314467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:31:54Z","timestamp":1760545914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641117314467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":53,"alternative-id":["S0939641117314467"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.02.001","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Composite films for vaginal delivery of tenofovir disoproxil fumarate and emtricitabine","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}